Theranica, a neuromodulation therapeutics company advancing clinically validated, drug-free treatments for idiopathic pain conditions and setting a new standard of care in migraine with REN-based ...

NICE recommended rimegepant in 2023 for treating migraine and preventing episodic attacks (between 4 and 14 migraines per month), and atogepant in 2024 for preventing both episodic and chronic ...

Thirteen percent of Americans—about 38 million people—suffer from migraine, and every one of them has a different experience with the condition. Treatment has to be as individualized as they are.

As CGRP-targeted therapies move into wider use, new data are beginning to clarify their role in special populations, the value of switching agents when one fails, and their long-term vascular safety.

A migraine attack is not just a “bad headache”. Migraine is a debilitating neurological condition which can cause nausea, vomiting, and sensitivity to light or sound, in addition to severe headaches.

Slate Medicines’ antibody drug is designed to block PACAP, a protein associated with migraines.

Among pediatric patients with available data, 72.2% (13/18) reported consistent headache relief and 36% (9/25) reported consistent freedom from headache. The Food and Drug Administration (FDA) has ...

Triangle Business Journal will recognize the robust growth of the Life Sciences sector in the Triangle. Nominations will be ...

When you buy through links on our articles, Future and its syndication partners may earn a commission. A GLP-1 agonist, the same class of drugs as Ozempic, may treat migraine, a study finds. | Credit: ...

Migraine sufferers are no strangers to major headaches. The onset of a migraine can be painful, disorienting and sometimes even debilitating. During National Migraine and Headache Awareness Month, Fox ...

Emgality is a monthly subcutaneous injection used to prevent episodic and chronic migraine. Migraine is a condition that causes intense throbbing or pulsating on one side of the head. Migraine may ...

Lundbeck A/S has announced encouraging new data from the intravenous part of its phase 2b PROCEED trial, showing that ...